Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Table of Contents What Is Retatrutide and Its Current Development Status in the UK Risks of Sourcing Unregulated Peptides Online MHRA Guidance on Unlicensed Weight Loss Treatments Approved Alternatives Available Through NHS and Private Clinics How to Speak to a UK Doctor About Emerging Weight Loss Options Scientific References Frequently Asked Questions What Is Retatrutide and Its Current Development Status in the UK Retatrutide is an investigational triple incretin receptor agonist (GLP-1, GIP, and glucagon) developed by Eli Lilly that remains in Phase 3 trials and holds no MHRA marketing authorisation as of mid-2025
Optimal: personalized targets that maximize health, vitality, energy, and performance
Many people view GLP-1s as a path to lose weight faster, especially when it feels like nothing else works
While the market is crowded with weight loss support and medications, few resources offer personalized insight into the simple question: What can I expect?
